Ernexa Therapeutics Inc. (ERNA)
Develops engineered stem cell therapies to fight cancer and autoimmune diseases
$3.61-0.08%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-90.7%
The outlook
ERNA is trading near its 52-week low, well below both its 50- and 200-day moving averages. Analyst price targets average around $27, suggesting significant upside, though current sentiment scores bearish. The stock remains in a weak downtrend despite the bullish longer-term target consensus.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range1% of the way from its 52-week low to high
Price targetAvg target +731% vs current price
Market cap
$4.2M
52-wk high
$71.50
52-wk low
$3.18
50-day avg
$7.37
200-day avg
$17.55
Trailing P/E
—